Study Closeout & Results Disclosure
Ending a study properly: site closeout and reconciliation, the clinical study report, registry disclosure and results posting, record retention, and communication back to participants. Disclosure is a legal duty with deadlines, enforced regardless of whether the result was favourable. Closeout is also the last point at which a missing record can still be recovered from a site that still exists.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSCloseout is where the record is made permanent and disclosure is where it becomes public — and both are the least resourced parts of a study, run after the people who ran it have moved to the next one.
06 · QUALITY MATURITY — STUDY CLOSEOUT & RESULTS DISCLOSURE, REACTIVE TO ADAPTIVE
Closeout happens when someone gets to it. The trial master file is reconciled long after the team dispersed.
A closeout checklist exists and is worked through, but file completeness is assessed at the end rather than maintained during conduct.
The file is complete and contemporaneous throughout, database lock follows defined criteria, and disclosure obligations are tracked per registry with owners and dates.
Disclosure content is prepared alongside the report rather than after it, and results are posted within obligation regardless of the programme’s commercial position.
The record is inspection-ready at any point, and what the study learned is captured for the programme rather than only for the report.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: ICH, FDA, EMA.
RECORDS & OBJECTIVE EVIDENCE
- Trial master file completeness assessment, and evidence it was maintained during conduct
- Database lock criteria and the record of lock
- The registry obligation list per jurisdiction, with owners and due dates
- Posted results and their submission dates against those obligations
- Archiving arrangements, including retention period and retrievability
COMMON INSPECTION FINDINGS
- A trial master file reconstructed at closeout rather than maintained during conduct
- Database lock performed with open queries or unresolved discrepancies
- Results disclosure late or absent for a study that completed
- Disclosure obligations tracked for some registries and not others
- Archived records that cannot be retrieved or read within the retention period
Reconciliation while the site still exists
Closeout is the final opportunity to reconcile: investigational product accountability, source records against the database, the trial master file against what should be in it, and unresolved queries. Once a site closes, staff disperse, systems are decommissioned and paper is archived by someone with no context — and a gap found afterwards may simply be unrecoverable.
The trial master file is where this bites hardest at inspection. A TMF that is complete at closeout is a record; one reconstructed two years later from correspondence is an exercise in explaining absence. Reconciliation is unglamorous work performed under schedule pressure at exactly the moment attention has moved to the next study.
The clinical study report is an argument with an audience
ICH E3 defines the structure and content of a clinical study report, and its purpose is to present the study completely enough that a reviewer can reach their own conclusion — including the parts that do not support the sponsor’s. Selective emphasis is visible to experienced reviewers and costs credibility across the whole submission, not only the section it appears in.
The practical discipline is that the report should describe what happened, including protocol deviations and their assessed impact, discontinuations and their reasons, and analyses that were pre-specified versus post hoc. A report that reads as though everything went to plan invites the question of what was omitted.
Disclosure runs on its own clock
Registry registration and results posting are statutory obligations with defined timelines, and they apply irrespective of the outcome or of whether the sponsor intends to publish. In the EU, Regulation (EU) 536/2014 attaches transparency requirements to trials conducted under it; equivalent obligations exist in the US and elsewhere, each with its own scope and deadline.
These obligations are missed not through decision but through ownership: they sit between medical writing, regulatory affairs and clinical operations, and the deadline arrives while each assumes another is tracking it. A disclosure register with named owners and dates per trial per jurisdiction is the entire control, and its absence is why enforcement actions in this area are so consistently about lateness rather than about content.
SPEQ interpretation — closing the loop with participants
Returning results to the people who took part is now an expectation in several jurisdictions and remains, in practice, the item most often quietly dropped. It is genuinely difficult — the results have to be accurate, comprehensible to a non-specialist, and produced long after the study team has moved on.
SPEQ’s view is that it should be planned as a closeout deliverable with an owner rather than treated as a communications afterthought, for a reason beyond compliance: participants who never hear anything are the ones who decline the next study. Trial recruitment feasibility is a shared resource, and how a sponsor ends a study affects the population available to everyone.
FREQUENTLY ASKED
Why does closeout reconciliation matter so much?
Because it is the last point at which a missing record can be recovered from a site that still exists. After closeout, staff disperse, systems are decommissioned and paper is archived without context — so a gap found later may be unrecoverable, and at inspection a reconstructed trial master file is an exercise in explaining absence.
What should a clinical study report include that sponsors sometimes omit?
Protocol deviations and their assessed impact, discontinuations and their reasons, and a clear separation of pre-specified from post hoc analyses. ICH E3 exists so a reviewer can reach their own conclusion; a report reading as though everything went to plan invites the question of what was left out, and the credibility cost spreads beyond that section.
Do disclosure obligations depend on the trial outcome?
No. Registry registration and results posting are statutory duties with defined deadlines that apply regardless of the result or of publication intent. They are missed through ownership rather than decision — sitting between medical writing, regulatory affairs and clinical operations while each assumes another is tracking the date.
Is returning results to participants required?
It is an expectation in several jurisdictions and increasingly a formal requirement. Beyond compliance there is a practical argument: participants who never hear anything decline the next study, and recruitment feasibility is a resource shared across every sponsor.